Results 21 to 30 of about 8,424 (263)
Stabilization of eptifibatide by cosolvents [PDF]
International Journal of Pharmaceutics, 2001 Eptifibatide is a potent and highly specific inhibitor of platelet receptor glycoprotein IIb/IIIa and is indicated in the treatment of acute coronary syndrome. The commercial product Integrilin(R) (eptifibatide) Injection requires a cold/refrigerator storage condition.
Luwei Zhao, Samuel H. Yalkowsky
openalex +4 more sources
Acta Medica Iranica, 2020 Introduction: Platelets activation and aggregation play a major role in thrombosis formation of coronary arteries in patients with Acute Coronary Syndrome (ACS) and is responsible for most ischemic complications during PCI.
tooran makhdoumi
doaj +2 more sources
Cardiovascular Diabetology, 2008 Background The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β3 integrin inhibitors antagonize fibrinogen binding to αIIbβ3 integrins on platelets and ligand ...
Huang Jianhua +3 more
doaj +3 more sources
Clinical and economic studies of eptifibatide in coronary stenting
Therapeutics and Clinical Risk Management, 2014 Tilak Pasala, Prasongchai Sattayaprasert, Pradeep K Bhat, Ganesh Athappan, Sanjay Gandhi The Heart and Vascular Center, Case Western Reserve University/MetroHealth, Cleveland, OH, USA Abstract: Platelet adhesion and aggregation at the site of coronary ...
Pasala T +4 more
doaj +5 more sources
Comparison of eptifibatide and abciximab with decision analysis [PDF]
American Journal of Health-System Pharmacy, 2001 Dorothy H. Wong
openalex +4 more sources
Profound Thrombocytopenia Associated With Administration of Eptifibatide [PDF]
Laboratory Medicine, 2007 Acute profound thrombocytopenia may be associated with the administration of eptifibatide, a glycoprotein antagonist. A case report of a 61-year-old male is presented. The reported incidence of acute profound thrombocytopenia associated with eptifibatide is 0.1% to 1.0% and usually occurs within 24 hours following therapy.
Gifford Lum, Paula Szuflad
openalex +2 more sources
Journal of Pharmaceutical and BioTech IndustryPoor drug entrapment, burst release, and variable drug release profiles are the most critical challenges associated with biodegradable-polymer-based microspheres. In this study, biodegradable-polymer-based microspheres were used to entrap an antiplatelet
Anand Kyatanwar, Bala Prabhakar
openalex +2 more sources
Eptifibatide provides additional platelet inhibition in non-ST elevation myocardial infarction patients already treated with aspirin and clopidogrel: Results of the PEACE study [PDF]
, 2003 Bal-dit-Sollier, Claire +9 more
core +2 more sources
Correction: Latacz et al. Safety and Efficacy of Low-Dose Eptifibatide for Tandem Occlusions in Acute Ischemic Stroke. <i>Neurol. Int.</i> 2024, <i>16</i>, 253-262. [PDF]
Neurol IntLatacz P +5 more
europepmc +2 more sources
Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets [PDF]
Circulation, 2005 Background— Pretreatment is not the most common strategy practiced for clopidogrel administration in elective coronary stenting. Moreover, limited information is available on the antiplatelet pharmacodynamics of a 300-mg versus a 600-mg clopidogrel loading dose, and the comparative effect of ...
Paul A. Gurbel +5 more
openalex +4 more sources